| 序号 | 申报企业 | 药品代码 | 通用名 | 商品名 | 剂型 | 規格 | 转换比 | 包装材质 | 包裝 单位 生产企业名称 | 分包装企 业名称 | 药品上市许可 持有人 | A/B组 | 备注 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 75 | 广州白云山屋群 (药业)股份有限 公司 | ZA10DAA009401 0300423 | 安神补脑液 | 无 | 合剂 | 每支装10ml(含 维生素B15mg) | 12 | 玻璃瓶 | 广州白云山星群 盒 (药业)股份有限公 日 | | 广州白云山星群(药 业)股份有限公司 | | | | | | | | | | 1 | | | | | | | | | | | | | | | | | | | | | | | 据了解，浙江第六批集采合计纳入45个品种，化药33个，中成药12个，严格遵循"技术评审+价格评审"双轨制，将临床疗效、质量可靠性、安全性等核心 指标置于评审首位。为保障临床用药需求与供应稳定性，评审还设置A ...

Core Insights - Jilin Aodong Pharmaceutical Group Co., Ltd. has over 60 years of experience in the traditional Chinese medicine sector, focusing on the unique characteristics of the Changbai Mountain region and combining tradition with innovation to revitalize its brand [1][2] Group 1: Company Background and Development - The company originated from the state-owned Yanbian Dunhua Deer Farm established in 1957, forming a deep connection with local medicinal materials [1] - Jilin Aodong has built the largest GAP-certified deer breeding base in Asia and a medicinal material base in Changbai Mountain, establishing a resource library and database for local medicinal materials [1] - The company aims to become a leading enterprise in northern Chinese medicinal materials through a comprehensive industrial layout, including seedling nurseries and demonstration bases [1] Group 2: Technological Innovation and Quality Control - Jilin Aodong is breaking through traditional bottlenecks in Chinese medicine by integrating modern technology, transitioning from "experience-based manufacturing" to "intelligent manufacturing" [1] - The company has obtained 525 certifications for traditional Chinese medicine formula granules and has established an advanced traceability system for the entire industry chain to ensure medication safety [1][2] Group 3: Financial Strategy and Market Position - The dual-driven model of "healthcare + financial capital" supports the company's long-term strategy and adaptation to industry changes [2] - As the largest shareholder of GF Securities, Jilin Aodong also holds significant stakes in Shanghai Pharmaceuticals, Nanjing Pharmaceutical, and Liaoning Chengda, creating a capital synergy network across finance, pharmaceuticals, retail, and distribution [2] - The financial sector provides stable cash flow that supports the pharmaceutical business, ensuring high-quality development [2] Group 4: Future Outlook - Jilin Aodong plans to continue deepening research on the modernization of traditional Chinese medicine and extending its industrial chain layout [2] - The company aims to integrate into the "Healthy China" initiative, leveraging Changbai Mountain's medicinal materials, technological innovation, and capital collaboration to enhance its brand and contribute to the revitalization of the traditional Chinese medicine industry [2]

Group 1 - The company adheres to the strategy of "dual-driven by pharmaceutical health and financial capital," focusing on the full industrial chain of deer antler and core product innovation to revitalize its traditional Chinese medicine brand [1] - The company has invested over 46 million yuan in upgrading epidemic prevention facilities, ensuring a zero-positive record for brucellosis and tuberculosis since 2021, thus maintaining a closed-loop management of deer antler raw materials [1] Group 2 - The company’s core product, the Anshen Bnnao Liquid, has sold nearly 10 billion units and generated annual revenue exceeding 700 million yuan, capturing over 70% of the national market share in its category [2] - The company plans to increase R&D investment during the 14th Five-Year Plan, focusing on the core material research of deer antler and advancing into the fields of anti-aging and regenerative medicine [2] Group 3 - The company emphasizes that its full industrial chain layout serves as both a quality "moat" and a stabilizer against cost fluctuations, while also fulfilling social responsibilities [3] - The company has implemented cash dividends for 18 consecutive years, totaling 4.739 billion yuan, reinforcing its commitment to long-term value growth [3]

Group 1 - Jilin Aodong Pharmaceutical Group actively participated in the "Hundred Enterprises Connect Hundred Villages" initiative, donating essential medicines worth RMB 594,900 to nine poverty alleviation villages in Tibet [1] - The donated medicines include four types of urgently needed common drugs, which will be distributed to 1,147 farming and pastoral households, enhancing local healthcare resources [1] - The company is committed to the development of traditional Chinese medicine (TCM) through innovation and industry upgrades, integrating traditional characteristics with modern elements [1] Group 2 - Jilin Aodong focuses on core research of traditional Chinese medicinal materials, advancing into anti-aging and regenerative medicine, and transitioning TCM from "experience inheritance" to "scientific decoding" [2] - The company has obtained two significant invention patents, upgrading core products to meet high-quality health consumption demands [2] - Jilin Aodong is enhancing the entire TCM industry chain's intelligent upgrade through new production capabilities, utilizing biotechnologies and smart management systems for better quality control [2] Group 3 - The company has secured 525 filing certificates in the TCM granule sector and is leading industry standard research in collaboration with universities, filling market gaps and guiding industry development [3] - Jilin Aodong is reconstructing a health ecosystem centered around deer antler, significantly increasing the knowledge density and value of the entire industry chain [3] - The company aims to drive industry upgrades through technological innovation and standardization, aligning with the "Healthy China" strategy and the 14th Five-Year Plan [3]

Core Viewpoint - Jilin Aodong's Anshen Bnona Liquid has maintained a leading position in the domestic market for over 42 years, achieving cumulative sales of 8 billion bottles and a market share exceeding 80% [1][12] Group 1: Product Quality and Market Position - Anshen Bnona Liquid is recognized as a core product of Jilin Aodong, generating a total profit of 2.1 billion yuan and contributing 1.5 billion yuan in taxes to the state [1] - The product has been included in the first batch of protected traditional Chinese medicine varieties and the national medical insurance catalog, highlighting its significance in the industry [1][8] - The product's success is attributed to the use of high-quality, authentic medicinal materials sourced from the Changbai Mountain region, particularly the purebred velvet antler from the local deer [2][3] Group 2: Technological Innovation and Quality Control - Jilin Aodong has implemented modern production techniques, resulting in a 15% higher content of active ingredients like uridine and IGF-1 compared to ordinary deer antler [3][6] - The company has developed advanced technologies such as computer-controlled extraction and near-infrared online detection, ensuring product safety and consistency [6][8] - Continuous research and development efforts have led to the enhancement of production processes and quality standards, including the addition of new testing methods for raw materials [7][10] Group 3: Strategic Development and Policy Support - The company is positioned as a leading enterprise in the agricultural industrialization of Jilin Province, benefiting from government support for the development of the velvet antler industry [11] - Recent provincial policies encourage the secondary development of classic formulas and emphasize quality certification, aligning with Jilin Aodong's strategic goals [11] - The company aims to transform Anshen Bnona Liquid into a "ten billion-level product" by leveraging its market foundation and scientific breakthroughs [10][11]

Core Viewpoint - Jilin Aodong has evolved into a holding group company driven by both the pharmaceutical industry and financial capital, aiming to rejuvenate traditional Chinese medicine in modern society through innovation [6][13]. Company Development - Founded in 1957, Jilin Aodong has undergone significant transformations, including the establishment of a pharmaceutical factory in 1981, a shareholding reform in 1993, and its listing on the Shenzhen Stock Exchange in 1996 [6]. - The company has developed a comprehensive industrial chain in the pharmaceutical sector, integrating cultivation, research, production, testing, and sales [7]. Product Innovation - Jilin Aodong's core product, "Anshen Bnuna Liquid," has been a market leader for over 40 years, with a market share of 60% to 70% in its category, generating over 700 million yuan in annual sales [7]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the listing of 525 traditional Chinese medicine formula granules [9]. Technological Advancements - The company has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [10]. - The production process has transitioned to a fully automated system, enhancing efficiency and precision in drug manufacturing [10]. Market Expansion - Jilin Aodong is expanding into the health industry, producing over 200 health products, with some individual products generating over 1 million yuan in annual sales [11]. - The company is also investing in financial sectors, with a reported investment income of 1.206 billion yuan in the first half of 2025, a 53.67% increase year-on-year [12]. Financial Performance - In the first half of 2025, Jilin Aodong achieved a net profit of 1.282 billion yuan, a significant increase of 138.44% compared to the previous year [12]. - The company's total assets reached 34.151 billion yuan, with a debt-to-asset ratio of 11.54%, indicating a strong financial position [12]. Social Responsibility - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has contributed to local economic development through agricultural projects, generating 7.76 billion yuan in output value over the past decade [12].

Core Viewpoint - Jilin Aodong aims to transform traditional Chinese medicine into a modern enterprise through innovation and sustainable development, establishing itself as a leading pharmaceutical company with a dual focus on "pharmaceutical health + financial capital" [2][9]. Group 1: Company History and Development - Jilin Aodong has evolved from a state-owned deer farm established in 1957 to a publicly listed holding company, with significant milestones including the founding of a pharmaceutical factory in 1981 and its listing on the Shenzhen Stock Exchange in 1996 [2]. - The company has developed a comprehensive industrial chain in deer product processing, leveraging over 60 years of experience in breeding deer and achieving GAP certification for its breeding base [3]. Group 2: Product and Market Position - Jilin Aodong's core product, "Anshen Bunan Liquid," has been a market leader for over 40 years, holding a 60% to 70% market share in its category and generating over 700 million yuan in annual sales [3][8]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the registration of 525 traditional Chinese medicine formula granules, leading in registration numbers in Jilin Province [5]. Group 3: Innovation and Technology - Jilin Aodong has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [6]. - The company is embracing digital transformation, moving from experience-based production to data-driven processes, enhancing efficiency and product quality [6]. Group 4: Financial Performance - In the first half of the year, Jilin Aodong reported a net profit of 1.282 billion yuan, a significant increase of 138.44% year-on-year, with total assets reaching 34.151 billion yuan, up 3.48% from the beginning of the year [8]. - The company maintains a low debt ratio of 11.54%, indicating strong financial health within the industry [8]. Group 5: Social Responsibility and Community Engagement - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has created significant economic value for local communities through initiatives in ginseng and deer farming, generating 7.76 billion yuan in output value over the past decade [9]. - The company emphasizes its commitment to reinvesting profits into its pharmaceutical core business to support research, production upgrades, and market expansion [9].

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a significant increase in net profit despite a decline in revenue, demonstrating strong operational capabilities and strategic execution [1][4]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.126 billion yuan, a year-on-year decrease of 20.21% - The net profit attributable to shareholders reached 1.282 billion yuan, a year-on-year increase of 138.44% [1]. Business Structure - The traditional Chinese medicine segment remains the core business, generating sales revenue of 686 million yuan, accounting for 60.90% of total revenue - The chemical drugs, chain pharmacy wholesale and retail, and health industry segments contributed sales revenues of 143 million yuan, 187 million yuan, and 83 million yuan, representing 12.73%, 16.59%, and 7.39% of total revenue, respectively [1]. Strategic Initiatives - The company is actively reforming its marketing system in the traditional Chinese medicine segment, having completed the marketing restructuring of 22 products and adjusted pricing policies for over 50 products - The company has made significant progress in its Chinese medicine formula granule business, obtaining 525 registration certificates for market access [2]. - A plan to issue convertible bonds to raise 134 million yuan for capital increase in its subsidiary, aimed at constructing a project for Chinese medicine formula granules with an annual production capacity of 2,000 tons [2]. Market Trends - The recovery of the consumer market is expected to accelerate the sales of consumer-oriented traditional Chinese medicine - Long-term growth is supported by an aging population and increasing health awareness among residents, providing a solid foundation for the industry [3]. Operational Efficiency - The company has optimized operational efficiency and adjusted regional layouts by closing some chain pharmacy stores, while enhancing brand management and deepening industry chain collaboration - The chain pharmacy business added 73,000 new members during the reporting period [3]. Asset Management - As of June 30, 2025, the company reported total assets of 34.151 billion yuan, a 3.48% increase from the beginning of the year, and net assets of 29.960 billion yuan, a 3.21% increase - The asset-liability ratio stands at 11.54%, indicating a low level within the industry [4].

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities due to favorable policies and market developments, with a notable surge in stock performance among TCM companies [6][9]. Market Performance - On August 1, the A-share market saw a slight decline, with the Shanghai Composite Index down 0.37%, Shenzhen Component Index down 0.17%, and ChiNext Index down 0.24%. However, over 3,300 stocks rose in the market [1][2]. - The TCM sector led the market with a substantial increase, as evidenced by the 1.78% rise in the Shenwan TCM Index, with several companies, including Weikang Pharmaceutical and Tianmu Pharmaceutical, hitting the daily limit [5][6]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research and development [6]. - The State Council's 2025 directive emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [6]. Company Performance - Notable TCM companies reported significant profit growth in the first half of 2025. For instance, Darentang's net profit is expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [9][11]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [9][11]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced sales in pharmaceuticals and medical devices [10]. Investment Insights - Analysts suggest that the TCM sector is poised for growth, driven by innovative products and strong brand recognition, particularly in high-value markets [7][8]. - The focus on stable cash flow to support R&D expenditures is expected to be a key strategy for TCM companies moving forward [7].

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities, driven by policy support and strong performance in the stock market [1][2]. Market Performance - On August 1, the A-share market saw a mixed performance with the Shanghai Composite Index down 0.37%, Shenzhen Component down 0.17%, and ChiNext down 0.24%, while over 3,300 stocks rose [1]. - The TCM sector witnessed a surge, with the Shenwan TCM Index rising by 1.78%, placing it among the top-performing secondary industry indices [2]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research [2]. - The State Council's 2025 policy emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [2]. Company Performance - Notable companies such as Darentang, Jilin Aodong, and Buchang Pharmaceutical reported significant net profit growth, with Darentang's net profit expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [4][5]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [5]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced market strategies and sales [5]. Financial Highlights - The following companies reported substantial net profit growth in the first half of 2025: - Darentang: 19.2 billion yuan, up 192% [6] - Jilin Aodong: 12.63 billion yuan, up 135% [6] - Buchang Pharmaceutical: 5.98 billion yuan, up 158.41% [6] - The overall performance of TCM companies indicates a strong recovery and growth trajectory, supported by favorable market conditions and policy initiatives [4][5].